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Abstract
Aims: To confirm the stress-relieving effects of heat-inactivated, enteric-
colonizing Lactobacillus gasseri CP2305 (paraprobiotic CP2305) in medical
students taking a cadaver dissection course.
Methods and Results: Healthy students (21 males and 11 females) took
paraprobiotic CP2305 daily for 5 weeks during a cadaver dissection course.
The General Health Questionnaire and the Pittsburgh Sleep Quality Index were
employed to assess stress-related somatic symptoms and sleep quality
respectively. The aggravation of stress-associated somatic symptoms was
observed in female students (P = 0029). Sleep quality was improved in the
paraprobiotic CP2305 group (P = 0038), particularly in men (P = 0004).
Among men, paraprobiotic CP2305 shortened sleep latency (P = 0035) and
increased sleep duration (P = 0048). Diarrhoea-like symptoms were also
effectively controlled with CP2305 (P = 0005) in men. Thus, we observed sex-
related differences in the effects of paraprobiotic CP2305. In addition, CP2305
affected the growth of faecal Bacteroides vulgatus and Dorea longicatena, which
are involved in intestinal inflammation.
Conclusions: CP2305 is a potential paraprobiotic that regulates stress
responses, and its beneficial effects may depend on specific cell component(s).
Significance and Impact of the Study: This study characterizes the effects of a
stress-relieving para-psychobiotic in humans.
Introduction
Several lines of evidence suggest that certain lactic acid
bacteria significantly modulate communication in the
gut–brain axis through neural, endocrine and immune
signalling pathways (Cryan and Dinan 2012), allowing
them to alter stress sensitivity (De Palma et al. 2014).
Studies employing experimental animals have demon-
strated that the administration of specific probiotics eases
stress-induced glucocorticoid and inflammatory cytokine
responses in conjunction with the reduction of depres-
sion- and anxiety-related behaviours (Gareau et al. 2007;
Bravo et al., 2011; Bercik et al. 2011). In clinical trials,
certain probiotics have alleviated psychological distress in
healthy subjects by normalizing stress-induced reductions
in natural killer cell numbers (Marcos et al. 2004) and
gastrointestinal symptoms (Diop et al. 2008). However,
the scientific evidence supporting this concept remains
insufficient, particularly in humans.
There is considerable variety in the genetic diversity
and microbial properties of probiotic microbes, particu-
larly in terms of their physiological functions, which vary
from genus to genus, from species to species and even
between strains (Million et al. 2012). Probiotics were
originally defined by Fuller (1989) and then redefined as
“live microorganisms that, when administered in ade-
quate amounts, confer a health benefit on the host”
(Joint Food and Agriculture Organization of the United
Nations/World Health Organization, 2016) based on
research investigating the underlying mechanism. Fur-
thermore, there is increasing evidence that nonviable
microbial cells, cell lysates, semipurified microbial frac-
tions or purified substances exert beneficial effects on
human and animal health as “biogenics” (Mitsuoka 2014)
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or “paraprobiotics” (Taverniti and Guglielmetti 2011).
The underlying mechanisms of these paraprobiotic effects
suggest a direct interaction between host cells and bacte-
rial components or products (Taverniti and Guglielmetti
2011). Usage of these bacterial cell components or prod-
ucts derived from them has notable advantages for the
development of safer and more stable products for indus-
trial use (De Almada et al. 2016).
To elucidate the exact working mechanism(s) of bene-
ficial microbes during stress relief, it is important to clar-
ify which microbe-derived bioactive compound(s) exert
stress-relieving effects. We are particularly interested in
the probiotic Lact. gasseri strain CP2305 (CP2305). The
unique CP2305 strain colonized the digestive tracts of
ca. 40% of volunteers after three-time oral administration
at a dose of 10 9 1011 CFU (Sawada et al. 2016). This
strain had an antiflatulent effect, especially in constipated
volunteers, and significantly changed the microbiota
composition. Similar to live CP2305, heat-inactivated
CP2305 improved bowel habits in healthy volunteers by
correcting the balance between sympathetic and parasym-
pathetic nerve activities (Sugawara et al. 2016). Thus,
CP2305 may effectively modulate brain–gut axis activity
and exert stress-relieving effects. Indeed, we reported that
CP2305 relieves stress in healthy young adults under
stressful conditions (Sawada et al. 2017) and improves
the clinical symptoms of irritable bowel syndrome (IBS)
(Nobutani et al. 2017). Moreover, we considered the
possibility that bacteria-derived bioactive compound(s)
exert the stress-relieving effects induced by CP2305
without requiring bacterial metabolic activity or product
release. To investigate this hypothesis, we performed the
current study to examine the effects of heat-inactivated
CP2305 (paraprobiotic CP2305) in the form of a
fermented milk-based beverage, using a beverage prepared
from lactic acid-acidified, nonfermented milk as the
placebo.
A brief, naturalistic stress, such as an academic exami-
nation, is a useful model for the investigation of physical
and psychological stress responses in healthy subjects.
However, examination stress is an acute stress model that
activates the hypothalamus–pituitary–adrenal (HPA) axis
for only a short period of time (Kurokawa et al. 2010;
Kamezaki et al. 2012). To clarify the beneficial effects of
probiotic CP2305 on stress-related behaviours under
more stressful situations that last for longer periods of
time, we employed medical students taking a cadaver dis-
section course as described in a previous study (Sawada
et al. 2017), although there were two major differences.
First, the present experimental design employs a parallel
competitive design rather than a crossover design
(Sawada et al. 2017) to eliminate carry-over effects. Sec-
ond, the previous study included only male students,
while both male and female students were employed in
the present study to examine sexual differences. Thus, we
performed this study to confirm the stress-relieving
effects of the heat-inactivated paraprobiotic CP2305 in a
double-blinded, placebo-controlled and parallel-group
comparison trial as a first step.
Materials and methods
Supplementary beverages
Two types of acid milk beverages were prepared: a beverage
containing sterilized CP2305-fermented milk and a placebo
beverage. The constituents of the beverages are shown in
Table 1. The placebo beverage was prepared from a bacte-
ria-free, artificial sour milk base by adding flavouring and
granulated sugar and performing acidification with lactic
acid. The test and placebo beverages were indistinguishable
based on an organoleptic examination performed by test
panels. Both beverages were canned as 190-g (daily intake
dosage) doses in 200-ml containers. The CP2503-contain-
ing test beverage contained 1 9 1010 bacterial cells per
container. The primary CP2305-fermented milk was pre-
pared with base constituents of 10% (w/w) skimmed milk
plus 025% (w/w) yeast extract at 37°C for 18 h. After
preparation of the final mixtures of the test beverages,
including the intermediate materials and fermented milk,
final sterilization was performed using a continuous steril-
izer at 95°C for 30 s. No living bacteria were detected in
either the test beverage or the placebo beverage.
Experimental design
We recruited 32 subjects who were second-year undergrad-
uate medical students at Tokushima University, Tokush-
ima, Japan. The students included both sexes (21 males
and 11 females) and were 18–34 years of age. Participants
were not habitual smokers and did not take any medication
for 3 months prior to enrolment. None of the students had
Table 1 Constituents of the beverages
Beverages
Constituent (w/w %) CP2305 Placebo
CP2305-fermented milk 5263 0
Skim milk powder 0 5263
Yeast extract 0 00132
Granulated sugar powder 8 8
Stabilizer 035 035
Lactate (50%) 1012 1137
Sodium citrate 01842 01842
Yoghurt flavour 01 01
Water 377238 849526
Total 100 100
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psychological or physical disorders or milk or other food
allergies (Table 2). All students took the cadaver dissection
course from September 4 to December 12. The students
were randomly divided into two groups: participants allo-
cated into one group consumed the placebo beverage, and
participants in the other group consumed the test beverage
containing heat-inactivated CP2305. They consumed the
provided beverage daily for 5 weeks from September 4 to
October 9, 2007 (Fig. 1). Daily consumption was self-
recorded in a diary to verify the compliance rate of
ingestion. During the trial, the subjects complied with diet-
ary restrictions by avoiding the consumption of other fer-
mented milks, fermented foods, beverages containing
living lactic acid bacteria, and probiotic or prebiotic prod-
ucts. Medications and hospital visits were allowed and
recorded in a diary if these events occurred. This study was
performed in accordance with the ethical standards
described in the 1964 Declaration of Helsinki, and all pro-
cedures involving human subjects were approved by the
Institutional Review Board of Tokushima University
Hospital, Tokushima, Japan. Written informed consent
was obtained from all subjects prior to enrolment.
Questionnaires to assess mental and physical status
The physical and mental health of the participants were
assessed using the following questionnaires: GHQ-28, the
28-item General Health Questionnaire (Goldberg and
Hillier 1979); Zung-SDS, the Zung Self-rating Depression
Scale (Zung 1965); HADS, the Hospitality Anxiety and
Depression Scale (Zigmond and Snaith 1983); and STAI,
the Spielberger State-Trait-Anxiety-Inventory (Kvaal et al.
2005). Sleep was evaluated using the Pittsburgh Sleep
Quality Index (PSQI) (Buysse et al. 1989), which assesses
sleep quality and disturbances over a 5-week time inter-
val. These questionnaires were given to the subjects at the
time of saliva sampling. We analysed the differences
before and after the intervention using the independent t-
test. The level of significance was set at a P value of 005.
When determining the significance of sex differences,
two-way analysis of variance was stratified to describe the
background.
Questionnaires to assess gastrointestinal symptoms and
eating disturbances
The gastrointestinal symptoms of the participants were
assessed using a 100-mm visual analogue scale (VAS)
concerning abdominalgia, feeling of indigestibility,
anorexia, borborygmus, abdominal distension, abdominal
discomfort, diarrhoea, constipation, frequency of defeca-
tion and colour features of faeces. Eating behaviour was
also assessed using the Eating Attitudes Test with 26
items (EAT-26), a self-reported measure of eating disor-
der symptoms that is widely used to screen and measure
the symptoms and characteristics of eating disorders
(Garner et al. 1982). We analysed the differences before
and after the intervention using the independent t-test.
The comparison method chosen for analysis depended on
the distribution of the data. The level of significance was
set at a P value of 005. When determining the signifi-
cance of sex differences, two-way analysis of variance was
also applied to describe the background in detail.
Table 2 Characteristics of the participants
Initial scores
Questionnaire Treatment Mean SEM
GHQ28
Total score Placebo 1788 139
CP2305 2256 188
HADS
Depression Placebo 475 062
CP2305 625 081
Anxiety Placebo 500 058
CP2305 606 089
STAI
State anxiety Placebo 3788 261
CP2305 4381 269
Trait anxiety Placebo 4150 282
CP2305 4650 281
PSQI
Sleep habit (global) Placebo 438 052
CP2305 543 068
Age Mean SEM
Placebo 2131 090
CP2305 2075 040
Sex (M/F)
Placebo (10/6)
CP2305 (11/5)
Group 1
Group 2 CP2305 Washout
Sampling Sampling Sampling
Placebo Washout
Administration
for 5 weeks
Post-observation
for 5 weeks
Figure 1 Examination schedule. Participants were divided into two
groups. Participants in group 1 received the placebo, and those in
group 2 received CP2305. Biological samples and questionnaire
responses were obtained at the start and end of each experimental
period and after a postobservation period of 5 weeks.
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Measurements of salivary cortisol, alpha-amylase and
chromogranin A
Saliva was collected for 2 min between 16:00 and 17:00
to avoid diurnal fluctuations using a Salivette sampling
device (Sarstadt Inc., Rommelsdorf, Germany) prior to
the collection of blood (Kurokawa et al. 2010) and was
stored at 80°C until analyses were performed. Salivary
chromogranin A (CgA), cortisol, and alpha-amylase were
assayed using kits (YK070 Human CgA EIA kit, Yanai-
hara Institute, Shizuoka, Japan; cortisol EIA kit and
alpha-amylase assay kit, Salimetrics Inc., LLC, Carlsbad,
CA, USA). We analysed the differences before and after
the intervention using the independent t-test. The level of
significance was set at a P value of 005.
Analysis of the faecal microbiota
The faecal microbiota was analysed using faecal bacterial
16S rRNA V6–V8 region-targeted pyrosequencing. Faecal
samples (1–2 g) were collected in sterilized plastic tubes by
the patients. A pyrosequencing-based analysis based on the
method described by Nakayama (Nakayama 2010) was
performed to assess the compositional changes in the fae-
cal microbiota. Briefly, whole bacterial DNA was extracted
from 100 mg of faeces. Bacterial cells were lysed by beating
with zirconium beads in a 100 mmol l1 Tris-HCl buffer
(pH 90) containing 40 mmol l1 EDTA and 1% sodium
dodecyl sulphate. Bacterial DNA was first extracted using a
phenol/chloroform/isoamyl alcohol mixture and then pre-
cipitated with a polyethylene glycol solution. Purified DNA
was used as a template for the following two-step poly-
merase chain reaction (PCR) procedure. In the first round
of PCR, the V6–V8 fragment of 16S rDNA was amplified
with the 968F and 1390R primers without a barcode tag.
The second round of PCR was performed to attach a sam-
ple ID tag using primers containing four-base barcode
sequences. The amplicon was purified, and its concentra-
tion was measured using an IMPLEN NanoPhotometer
(Implen GmbH, Munich, Germany). Equal amounts of
amplicons derived from different samples were subjected
to oil emulsion PCR to produce millions of copies of clo-
nal DNA fragments captured on fine beads. The beads
were spread onto a pico-titre plate to include one bead
per well. Pyrosequencing reactions were performed in each
well to generate sequential luminescence that was moni-
tored using a CCD camera. A one million-well titre plate
containing 2 9 1/8 regions was used to analyse 128 sam-
ples. Pyrosequencing was performed using a Roche GS
FLX (Roche Diagnostics Japan, Tokyo, Japan). Individual
changes in the per cent composition of identified bacteria
before and after treatment were compared using Welch’s t-
test. Next, a discrimination analysis was performed to
assess the significance using JMP11 Pro (SAS Institute
Japan Inc., Tokyo, Japan).
Results
Mental status and sex differences
Paraprobiotic CP2305 significantly suppressed the aggrega-
tion of physical and mental health assessed by changes in
total GHQ-28 scores (Fig. 2a). The scores remained
unchanged changed in the paraprobiotic CP2305 group,
while the average scores changed from 179 to 203 in the
placebo group (P = 0380; Fig. 2a). Although there was no
significant change in the GHQ-28 total score when all sub-
jects were included, significant improvement with parapro-
biotic CP2305 ingestion was observed in females
(P = 0046) (Fig. 2c). Two-way ANOVA indicated a signifi-
cant probability of the “interaction of the treatment and
sex” (P = 0022), suggesting significant differences in the
responses to paraprobiotic CP2305 between males and
females. Paraprobiotic CP2305 significantly suppressed the
aggregation of somatic symptom scores of the GHQ-28. The
average score changed from 431 to 420 in the paraprobiotic
CP2305 group, while the placebo group exhibited a change
from 388 to 406 (P = 0029; Fig. 2b). By sex, the improve-
ment of somatic symptoms assessed with the GHQ-28 was
significant in females (P = 0042; Fig. 2d) but not in males
(P = 0340; Fig. 2d). Two-way analysis of variance (two-
way ANOVA)-stratified analysis showed that the signifi-
cances of the factors of ‘treatment’, ‘sex’ and ‘interaction of
the two factors’ were P = 0007, P = 0049 and P = 0062
respectively. Significant changes in the other components of
the GHQ-28, namely, ‘anxiety and insomnia’, ‘social disor-
ders’ and ‘severe depression’, were not observed.
Paraprobiotic CP2305 administration significantly
improved sleep quality as evaluated by changes in global
PSQI scores (P = 0038; Fig. 3a and d). The scores chan-
ged from 544 to 404, which were close to the threshold
value, in the paraprobiotic CP2305 group. The improve-
ment in the PSQI scores was observed in male students
(P = 0004; Fig. 3d) but not in females (P = 0760;
Fig. 3d). In stratified analysis of the males, of the seven
components of the PSQI, paraprobiotic CP2305 signifi-
cantly improved the ‘latency’ (P = 0035, Fig. 3e) and
‘duration’ (P = 0048, Fig. 3f) items. No significant dif-
ferences were observed in the other questionnaires.
Abdominal symptoms and salivary stress markers
We assessed stress-related abdominal symptoms using
questionnaires. While analyses that included all subjects
or only females did not show particular trends for the
tendency of diarrhoea (P = 0390, P = 0240 respectively;
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Fig. 4a and b), paraprobiotic CP2305 administration
effectively suppressed the tendency of diarrhoea among
male subjects during the cadaver dissection course. The
scores changed from 461 to 207 in the paraprobiotic
CP2305 group (P = 0005; Fig. 4b).
No significant differences were observed between the
CP2305 and placebo groups for salivary stress markers
(cortisol, CgA, and alpha-amylase).
Effects of paraprobiotic CP2305 ingestion on faecal
microbiota
Changes in the proportions of faecal bacteria were signifi-
cantly different between the placebo and CP2305 groups
for one phylum (Bacteroidetes), two specific genera
(Corynebacterium and Raoultella) and 15 specific species
(Bact. vulgatus, Barnesiella intestinihominis, Bifidobac-
terium bifidum, Cl. hathewayi, Cl. irregular, Cl. ruminan-
tium, Cl. straminisolvens, Eggerthella sinensis, Eubacerium
plautii, Hesperia porcina, Lact. animalis, Marvinbryantia
formatexigens, Robinsoniella peoriensis, Streptococcus
agalactiae and Weissella confusa) as determined by phy-
lum-level, genus-level and species-level analyses respec-
tively. Sex differences were not observed in these analyses.
Among the changes in bacterial group proportions at
the phylum level, only that of Bacteroidetes was
significantly decreased in the paraprobiotic CP2305 group
(P = 0040; Fig. 5a). Actinobacteria and Firmicutes
appeared to change but not significantly because of their
wide dispersion. Next, discrimination analyses using
genus-level data, in which differences in genera with
probabilities of less than 0229 were incorporated, pro-
vided a clear discriminant criterion (P = 0024; Fig. 5b).
Figure 5b shows the changes in the occupancy rates for
two species of bacteria, Bact. vulgatus and Dorea longi-
catena, that greatly contributed to this discrimination
along with the canonical species. Bact. vulgatus occupancy
was significantly decreased (P = 0022), while that of
Dorea longicatena was increased (P = 0054) in the para-
probiotic CP2305 group (Fig. 5c).
Discussion
Recently, we reported that live, enteric-colonizing CP2305
relieved stress-associated behaviours in healthy medical
students taking a cadaver dissection course (Sawada et al.
2017) and clinical symptoms in patients with IBS (Nobu-
tani et al., 2017). Here, we show for the first time that
heat-inactivated paraprobiotic CP2305 also exhibits
favourable effects on physical symptoms and sleep quality
in medical students during the same course. In this study,
paraprobiotic CP2305 did not significantly improve STAI
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state and HADS scores, both of which were significantly
reduced with live CP2305. However, the differing results
observed for live and heat-inactivated CP2305 must be
interpreted cautiously as there may be other causes for
these inconsistencies. One possible cause is the lack of
statistical power in this study due to the small number of
participants in the competitive parallel-group trial. In the
former trial, a small number of participants were also
employed, but the experimental design was a crossover
trial. Another important cause may be sex-related differ-
ences. Subjects of both sexes were employed in the
present trial, while only male students were examined in
the previous study (Sawada et al. 2017). There are likely
sex-related differences in the response to paraprobiotic
CP2305 (Spanakis et al. 2016). The paraprobiotic CP2305
improved sleep quality and bowel habits in male students
more effectively than in female students. There are sex
differences in several aspects of sleep behaviour, such as
quality, duration and chronotype, and in the risk of pro-
gressing from sleep disorder to insomnia (Adan and
Natale 2002; Bailey and Silver 2014). We also observed
the sleep disturbance-ameliorating effects of paraprobiotic
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CP2305 as well as sex-related differences associated with
these effects; daily paraprobiotic CP2305 intake resulted
in significant improvement only in male participants
(Fig. 2c). A previous study with IBS patients showed that
a probiotic composed of a complex of eight bacterial
strains increased melatonin synthesis and sleep quality
only in male patients (Wong et al. 2015). Differences in
stress responses resulting from the sex hormone balance
are well documented (Stephens et al. 2016). Although the
mechanism of action of paraprobiotic CP2305 is
unknown, it may be similar to the mode of action of the
eight-strain probiotic. In addition, we observed that the
paraprobiotic CP2305 ameliorated diarrhoea-like symp-
toms only in men. These sex dimorphisms in the para-
probiotic response may reveal its mode of action.
However, sex-related differences may also lead to a possi-
ble reduction in statistical detection power.
The microbiota profile is a dynamic entity that may be
influenced by many factors, including host genetics, age,
geography, diet, antibiotic treatment and exposure to
stressful conditions (Lozpone et al. 2012). Changes in the
gut microbiota may cause low-grade inflammation and
intestinal immune activation through their effects on
cytokine levels and toll-like receptor activity (Bercik 2011;
Hughes et al. 2013), thereby generating gut-related symp-
toms. Furthermore, the oral intake of beneficial bacteria
such as probiotics may help maintain intestinal perme-
ability (Camilleri et al., 2012), normalize circulating cyto-
kine levels (O’Mahony et al. 2005) and improve
peristalsis (Cani et al. 2013). The paraprobiotic CP2305
significantly affected the faecal microbiota as observed in
our previous studies (Sawada et al. 2016; Sugawara et al.
2016). At the phylum level, the occupation ratio of Bac-
teroidetes was significantly reduced after the ingestion of
paraprobiotic CP2305 (P = 0040; Fig. 5a). At the genus
level, microbial community structures apparently differed
between the placebo and paraprobiotic CP2305 groups
(P = 0027; Fig. 5b). The constituent genera in the
microbiota that effectively contributed to this distinction
were Bacteroides and Dorea. In addition, at the species
level, Bact. vulgatus and Dorea longicatena showed charac-
teristic changes in the microbiota along the canonical 1
axis (P = 0022 and P = 0054 respectively; Fig. 5c).
Interestingly, according to a recent study, unrestricted
Bact. vulgatus expansion evokes a subclinical inflamma-
tory response, including IFN-c production (Ramanan
et al. 2014). Although further investigation is required,
the decrease in Bact. vulgatus occupancy in the parapro-
biotic CP2305 group may reduce the risk of intestinal
inflammation (Kishi et al. 2000). In addition, the popula-
tion of Dorea longicatena is increased during the remis-
sion phase in patients with Crohn’s disease (Mondot
et al. 2015), suggesting that this species curbs
inflammation in the digestive tract. The community
structure and bacterial networks in both groups indicated
that daily administration of the paraprobiotic CP2305
significantly modified the gut microbiome despite its low
administered dose (1 9 1010 counts per day). Moreover,
targeting specific species, including Bact. vulgatus and
Dorea longicatena, may facilitate precise modulations in
the overall microbial ecosystem resulting in the downreg-
ulation of inflammation in the gut mucosa, which may
be related to stress response regulation. The genus Dorea
also showed quite similar changes in our clinical trial
with IBS patients (Nobutani et al., 2016); thus, this phe-
nomenon might be closely related to the stress-relieving
effect of CP2305.
Elucidation of the working mechanism underlying the
stress-relieving effects of paraprobiotic CP2305 is an
important next step. It has long been believed that lactic
acid bacteria are not retained but instead pass through
the human digestive tract when ingested. However,
strains of Lact. gasseri, including CP2305, have been
reported to colonize the intestine based on an analysis of
the established microbiota after oral administration (Fuji-
wara et al. 2001; Sawada et al. 2016). The discovery that
CP2305 is a typical enteric colonizer may provide new
insights given the closeness of its interaction with the
intestinal tract.
In conclusion, CP2305 exerts stress-relieving effects,
even after sterilization. Based on these results, bacterial cell
component(s) may contribute to this activity. This study is
the first step to determine the possible microbial bioactive
compounds involved in the stress-relieving effects.
Although sex-related differences in the action of CP2305
were observed, heat-inactivated CP2305 treatment effec-
tively and favourably alleviated stress-associated symptoms.
Here, we propose the use of heat-inactivated CP2305 as the
first stress-relieving paraprobiotic. CP2305 is advantageous
given its potentially wide range of applications. To further
confirm the stress-relieving effects of paraprobiotic
CP2305, another trial of heat-inactivated, washed CP2305
cells encompassing a higher number of participants of both
sexes as well as a longer period of administration
(12 weeks) is currently underway.
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